Detalhe da pesquisa
1.
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.
Eur J Haematol
; 101(1): 68-77, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-29569742
2.
Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment.
Hemasphere
; 6(11): e794, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36325271
3.
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
Front Immunol
; 12: 686768, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34276674
4.
Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia.
EJHaem
; 2(3): 525-529, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35844699
5.
Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia.
Hemasphere
; 5(5): e564, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33912812
6.
Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients.
Oncoimmunology
; 10(1): 1935557, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34239773
7.
Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application.
Cancers (Basel)
; 11(7)2019 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31261914